First Horizon Advisors, Inc. Ascendis Pharma A/S Transaction History
First Horizon Advisors, Inc.
- $3.81 Billion
- Q2 2025
A detailed history of First Horizon Advisors, Inc. transactions in Ascendis Pharma A/S stock. As of the latest transaction made, First Horizon Advisors, Inc. holds 235 shares of ASND stock, worth $44,732. This represents 0.0% of its overall portfolio holdings.
Number of Shares
235Holding current value
$44,732% of portfolio
0.0%Shares
7 transactions
Others Institutions Holding ASND
# of Institutions
277Shares Held
61.8MCall Options Held
151KPut Options Held
226K-
Ra Capital Management, L.P. Boston, MA10.3MShares$1.96 Billion33.28% of portfolio
-
Westfield Capital Management CO LP Boston, MA5.48MShares$1.04 Billion4.42% of portfolio
-
Avoro Capital Advisors LLC New York, NY5.22MShares$993 Million13.16% of portfolio
-
Janus Henderson Group PLC London, X04.49MShares$854 Million0.4% of portfolio
-
Artisan Partners Limited Partnership Milwaukee, WI4.26MShares$810 Million1.14% of portfolio
About Ascendis Pharma A/S
- Ticker ASND
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 55,810,200
- Market Cap $10.6B
- Description
- Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult h...